Treatment or prevention of cancer and precancerous disorders
US8357720B2 · kind B2 · utility
0Cited by
9References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 10, 2009 |
| Grant date | Jan 22, 2013 |
| Priority date | — |
| Expiry date | Feb 26, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The NSAID, sulindac and/or its metabolites and derivatives, in combination with an agent that generates or induces reactive oxygen species (ROS), significantly enhances the killing of abnormal cells but does not affect normal cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against the abnormal cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.